| ¿µ¹® | arthritis | ÇÑ±Û | °üÀý¿° |
|---|---|---|---|
| ¼³¸í | °üÀý¿¡ ÀÏ¾î³ ¿°Áõ. ¿øÀο¡ µû¶ó ȳó¼º-°áÇÙ¼º-¸Åµ¶¼º µî °¨¿°¼º°ú ·ù¸¶Æ¼½º¿¡ ÀÇÇÑ °Í, ¿Ü»óÀ¸·Î ÀÎÇÑ °Í µîÀ¸·Î ³ª´«´Ù. ÀÓ»ó»óÀ¸·Î´Â ±Þ¼º°ú ¸¸¼ºÀ¸·Î ³ª´¶´Ù. 1. ±Þ¼º. ¨ç Àå¾×°üÀý¿°: º¸Åë ¿Ü»ó¿¡ ÀÇÇØ ÀϾ¸ç ¿øÀκҸíÀÇ °Íµµ ÀÖÀ¸³ª ´ë°³ ÇϳªÀÇ °üÀý¿¡¸¸ ¹ß»ýÇÑ´Ù. ¨è Àå¾×¼¶À¯¼Ò°üÀý¿°: ±Þ¼º°üÀý ·ù¸¶Æ¼½º ¶§¿¡ ÀϾ¸ç, °üÀý°³»¿¡ ȥŹÇÑ »ïÃâ¾×ÀÌ °íÀδÙ. ¼¶À¯¼ÒÀÇ °ÅÁþ¸·ÀÌ »ý°Ü ¿°ÁõÀÌ °¡¶ó¾É¾Æµµ ½ÉÇÑ ¿îµ¿Àå¾Ö¸¦ ³²±ä´Ù. ¨é ȳó°üÀý¿°: °üÀýÀÇ °³¹æÃ¢ ¶Ç´Â ÀÓÁú-¼ºÈ«¿-ÆÐÇ÷Áõ °°Àº Àü¿°º´¿¡ ´Ù¹ß¼ºÀ» º¸ÀδÙ. »ýÈÄ 1~2°³¿ùÀÇ À¯¾Æ´Â »À°¡ ½ÉÇÏ°Ô »óÇÏ¿© Ä¡·áÇÒ ¼ö ¾ø´Â Å»±¸¸¦ ÀÏÀ¸Å²´Ù. ¼ºÀο¡¼´Â »À¸·°ñ¼ö¿°¿¡ °É·Á ȳóºÎ°¡ ÅÍÁ® °í¸§ÀÌ °üÀý·Î µé¾î°¡´Â °ÍÀÌ ¸¹À¸¸ç, À̸¦ 2Â÷ȳó°üÀý¿°À̶ó°í ÇÑ´Ù. 2. ¸¸¼º. ¨ç Ư¼ö¿°Áõ: °áÇÙ¼º-¸Åµ¶¼º ȤÀº Áß³â ÀÌÈÄÀÇ ³²ÀÚ¿¡ ¸¹Àº ¿ä»êÀÇ ´ë»ç Àå¾Ö·Î ÀÎÇÑ Åëdz¼º °üÀý¿°ÀÌ ÀÖ´Ù. ¨è ´Ù¹ß°üÀý¿°: ¸¸¼º°üÀý ·ù¸¶Æ¼½º¿¡ ÀÇÇÑ °ÍÀÌ ¸¹À¸¸ç ±Þ¼ºÀå¾×°üÀý¿°¿¡¼ ÀÌÇàÇÑ °Í°ú °áÇÙ-¸Åµ¶-ÀÓÁúÀÇ °æ°ú Áß¿¡ º¼ ¼ö ÀÖ´Â ´Ù¹ß¼º ¹× ÆÐÇ÷ÁõÀÇ Çϳªµµ ÀÖ°í, ¿©±â¿¡´Â ½ºÆ¿º´À̶ó´Â °üÀý¿°µµ Æ÷ÇԵȴÙ. ¨é º¯Çü°ñ°üÀý¿°: »À³ª °üÀýÀÇ ³ëÈ ¶Ç´Â ¿Ü»óÀÌ ¿øÀÎÀÌ´Ù. ¨ê Ç÷¿ìº´°ýÀý¿°: Ç÷¿ìº´À» ¾ÎÀ» ¶§ °üÀý ³»ÀÇ ÃâÇ÷¿¡ ÀÇÇÑ °ÍÀÌ´Ù. |
||
| ¿µ¹® | rheumatoid arthritis | ÇÑ±Û | ·ù¸¶Æ¼½º°üÀý¿° |
|---|---|---|---|
| ¼³¸í | ¸¸¼ºÀÇ °üÀýº´À¸·Î º¸Åë ¿©·¯ °üÀýÀ» ħ¹üÇϸç, À±È°¸·(°üÀýÀ» µÑ·¯½Î°í ÀÖÀ¸¸ç, °üÀýÀÇ ¿òÁ÷ÀÓÀ» ¸¶Âû¾øÀÌ ¿øÈ°ÇÏ°Ô ¼öÇàµÇµµ·Ï ÇÔ), °üÀý±¸Á¶ÀÇ ¿°Áõ¼º º¯È¿Í »ÀÀÇ À§Ãà°ú ¼Ò¸ð°¡ µÎµå·¯Áø´Ù. ¸»±â¿¡´Â º¯Çü°ú °Á÷ÀÌ ÀϾ¸ç ¿øÀÎÀº ºÒ¸íÀ̳ª ÀÚ°¡¸é¿ª¼º ¶Ç´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°¿¡ ÀÇÇÑ °ÍÀ¸·Î »ý°¢µÈ´Ù. Ä¡·á´Â °è¿ÀÇ ¼Ò¿°ÁøÅëÁ¦°¡ »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | pelvic inflammatory disease | ÇÑ±Û | °ñ¹Ý¿°Áúȯ |
|---|---|---|---|
| ¼³¸í | °ñ¹ÝÁÖÀ§ÀÇ Àå±â¿¡ ¹ß»ýÇÏ´Â ¿°ÁõÀ» ¸»ÇÔ. ÁÖ·Î ¿©¼º¿¡¼ ¹ß»ýÇÏ¸ç ¿øÀÎÀº ÀÓ±Õ(gonococcus)°ú ºñÀÓ±Õ¿¡ ÀÇÇÑ °¨¿°(non-gonorrheal infection)¿¡ ÀÇÇÑ´Ù. Áõ»óÀº Ãʱ⿡´Â ÁúºÐºñ¹°, ÇϺ¹ºÎµ¿Åë, ¿©¼ºÀÇ »ý½Ä±âºÎÀ§¿¡ ¹ß»ýÇÏ´Â ¾ÐÅë, ¿ù°æÅë, ¿ù°æ·®ÀÇ Áõ°¡ µîÀÌ´Ù. ÀÏÂï Ä¡·áÇØ¾ß Çϸç, °è¼ÓÀûÀ¸·Î º´ÀÌ Áö¼Ó½Ã ¿©¼ºÀÇ ºÒÀÓÀÇ ¿øÀÎÀÌ µÈ´Ù. ÈÄÁø±¹¿¡¼´Â °¡Àå ¸¹Àº ¿©¼ººÒÀÓÀÇ ¿øÀÎÀ̱⵵ ÇÔ. Ä¡·á´Â Ç×»ýÁ¦ÀÇ Åõ¿©ÀÌ´Ù. |
||
| ¿µ¹® | chronic lymphocytic leukemia | ÇÑ±Û | ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´ |
|---|---|---|---|
| ¼³¸í | ¹éÇ÷º´(leukemia)¶õ ºñÁ¤»óÀûÀÎ ¹éÇ÷±¸ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÀÇÇØ ÀϾ´Â º´ÀûÀÎ »óŸ¦ ¸»Çϴµ¥, ÈçÈ÷ ¸»ÃÊÇ÷¾×¿¡ ¹ÌºÐȼ¼Æ÷°¡ ³ªÅ¸³ª¸ç, Á¤»óÀûÀÎ ÀûÇ÷±¸¼¼Æ÷¿Í ¹éÇ÷±¸¼¼Æ÷, Ç÷¼ÒÆÇÀÇ ±Þ°ÝÇÑ °¨¼Ò¸¦ °¡Á®¿Í Á¤»óÀûÀÎ ¼¼Æ÷¿¡ ÀÇÇØ ÇàÇØÁö´Â ¿©·¯ ±â´ÉÀÇ °¨¼Ò¸¦ ÁÖÁõ»óÀ¸·Î ÇÏ¿© º´¿ø¿¡ ã¾Æ¿À°Ô µÈ´Ù. µû¶ó¼ ÀûÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ºóÇ÷, ¹éÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ¸¹Àº °¨¿°Áõ¼¼(ÈçÈ÷ °É¸®Áö ¾Ê´Â ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°, Áö³ªÄ¡°Ô ÀæÀº °¨±â, Æó·Å µî), Ç÷¼ÒÆÇ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³´Ù. ¶ÇÇÑ ÇǸ¦ »ý»êÇÏ´Â °ñ¼ö Á¶Á÷¿¡¼´Â ÀÌ·± ºñÁ¤»óÀûÀÎ ¼¼Æ÷ÀÇ Áõ½Ä¸¸À» º¼ ¼ö ÀÖÀ¸¸ç, Á¤»óÀûÀÎ ¼¼Æ÷ÀÇ Áõ½ÄÀº º¸±â Èûµé´Ù. ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´Àº ¼¾ç¿¡¼´Â ºñ±³Àû ¹éÇ÷º´ Áß¿¡¼ ÈçÇÑ ÇüÀÌÁö¸¸ µ¿¾ç±Ç¿¡¼´Â ¾ÆÁÖ µå¹® ¹éÇ÷º´ÀÇ ÇüÅÂÀÌ´Ù. ´ë°³ 60¼¼ ÀÌ»óÀÇ °í·ÉÃþ¿¡¼ ¸¹ÀÌ »ý±â°í 30¼¼ ÀÌÇÏ¿¡¼´Â °ÅÀÇ Ã£¾Æº¼ ¼ö°¡ ¾ø´Ù. Ç÷¾×°Ë»ç»ó¿¡¼ ¸²ÇÁ±¸ÀÇ ¸¹Àº Áõ°¡¸¦ º¼ ¼ö°¡ ÀÖ°í, ´ë½Å¿¡ ´Ù¸¥ Ç÷¾×¼¼Æ÷µéÀº °¨¼Ò¸¦ ³ªÅ¸³½´Ù. ¹éÇ÷º´ Áß ¿¹Èİ¡ ÁÁÀº ÆíÀÌ¸ç ´ë°³ Ä¡·á´Â Ç×¾ÏÁ¦¸¦ ÀÌ¿ëÇÑ ÈÇпä¹ýÀ» ¸¹ÀÌ »ç¿ëÇϸç, Æò±Õ »ýÁ¸±â°£Àº 4~5³âÀÌ´Ù. |
||
| ¿µ¹® | chronic obstructive pulmonary disease | ÇÑ±Û | ¸¸¼ºÆó¼âÆóº´ |
|---|---|---|---|
| ¼³¸í | ¸¸¼ºÀûÀ¸·Î ±âµµÀÇ Æó¼â¸¦ °¡Á®¿À´Â º´À» À̸£´Â ¸». ´ë°³ ¸¸¼º±â°üÁö¿°, ±â°üÁö õ½Ä, Æó±âÁ¾ÀÇ 3°¡Áö º´À» ¸»ÇÑ´Ù. ¸¸¼º±â°üÁö¿°À̶õ ±â°üÁöÀÇ ¸¸¼º¿°ÁõÀ» ¸»ÇÑ´Ù. ±â°üÁöÀÇ ¿°ÁõÀ¸·Î ÀÎÇØ¼ ±â°üÁöÀÇ Á¡¸·¿¡ ºÎÁ¾ÀÌ »ý±â°í ÀÌ·Î ÀÎÇØ¼ ±â°üÁöÀÇ ³»°æÀÌ Á¼¾ÆÁ®¼ ±âµµÀÇ Æó¼â¸¦ °¡Á®¿Â´Ù. ´ë°³ Èí¿¬°ú ¹ÐÁ¢ÇÑ ¿¬°üÀ» °¡Áö¸ç, È£Èí°ï¶õ, ±âħ, ±×¸®°í °¡·¡(´ë°³ »öÀÌ Çª¸£°í Á¡µµ°¡ ³ôÀº °¡·¡)°¡ Áõ»óÀ¸·Î ³ªÅ¸³´Ù. Æó±âÁ¾Àº ±â°üÁöÀÇ º®À» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ ±â°üÁö°¡ Á¦ ¸ð¾çÀ» °®ÃßÁö ¸øÇÏ°í ¹«³ÊÁö°Ô µÇ¾î ±âµµÀÇ Æó¼â°¡ ÀϾ´Â º´ÀÌ´Ù. Áï ±â°üÁö°¡ °ü ¸ð¾çÀ¸·Î ÆØÆØÇÏ°Ô ÆìÁö´Â °ÍÀ» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ °ü¸ð¾çÀ¸·Î ÆìÁöÁö ¸øÇØ °á±¹Àº ÆóÆ÷³»¿¡ °ø±â°¡ Â÷°í ÆóÆ÷º®ÀÌ ÆÄ¿µÇ°í ±â°üÁö°¡ Á¼¾ÆÁö°Ô µÇ´Â º´À» ¸»ÇÑ´Ù. ±â°üÁöõ½ÄÀ̶õ ¿©·¯ °¡Áö Àڱؿ¡ ´ëÇØ¼ ±â°üÁö°¡ °ú¹ÎÇÑ ¹ÝÀÀÀ» º¸¿©¼ »ý±â´Â ±â°üÁöÀÇ °¡¿ªÀûÀÎ Æó¼â¸¦ ÀǹÌÇÑ´Ù. Áï Á¤»óÀο¡°Ô¼´Â ±â°üÁöÀÇ Æó¼â¸¦ º¸ÀÌÁö ¾Ê´Â Àڱؿ¡ ´ëÇØ¼ ±â°üÁöÀÇ Æó¼â°¡ »ý±â°í ±× ÀÚ±ØÀÌ ¾øÀ» °æ¿ì¿¡´Â ±â°üÁöÀÇ Æó¼â°¡ ¾ø¾îÁö´Â º´À» ¸»ÇÑ´Ù. |
||
| ABCDES | abnormal alignment, bones-periarticular osteoporosis, cartilage-joint space loss, deformities, margi... |
|---|---|
| JRA | Juvenile Rheumatoid Arthritis; ¿¬¼Ò±â ·ù¸¶ÅäÀÌµå °üÀý¿° = Juvenile Chronic Arthritis; ¿¬¼Ò±â ¸¸¼º °üÀý... |
| CP | candle power; capillary pressure; cardiac pacing; cardiac performance; cardiopulmonary; caudate puta... |
| CRD | carbohydrate-recognition domain; chronic renal disease; chronic respiratory disease; child restraint... |
| CIDP | chronic idiopathic polyradiculopathy; chronic inflammatory demyelinating polyradiculoneuropathy |
| JCA | Juvenile Chronic Arthritis |
|---|---|
| CIDP | Chronic Inflammatory Demyelinating Neuropathy |
| CIDP | Chronic Inflammatory Demyelinating Polyneuropathy |
| CIDP | Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
| CIBD | Chronic inflammatory bowel disease |
| chronic inflammatory demyelinating polyneuropathy | An uncommon, acquired, demyelinating sensorimotor polyneuropathy, clinically characterised by insidious onset, and slow evolution, (either steady progression or stepwise), and chronic course; symmetrical weakness is a predominant symptom, often involving proximal leg muscles, accompanied by paresthesias, but not pain; CSF examination shows elevated protein, while electrodiagnostic studies reveal evidence of a demyelinating process, primarily conduction slowing rather than block; sometimes responds to prednisone. (05 Mar 2000) |
|---|---|
| chronic inflammatory polyneuropathy | <neurology, pathology> A disorder that involves the slow progressive (or recurrent) inflammation of multiple nerves. Loss of movement and sensation are common findings. The exact cause is related to an abnormal immune response. The acute form of this illness is known as Guillain-Barre syndrome. Treatment often includes systemic corticosteroids or chemotherapeutic agents to suppress the immune system. Prognosis is variable. Origin: Gr. Pathos = disease (27 Sep 1997) |
| chronic absorptive arthritis | Arthritis accompanied by pronounced resorption of bone with shortening and deformity, especially of the hands; when the deformity is extreme, the condition has also been termed arthritis mutilans. (05 Mar 2000) |
| systemic-onset juvenile chronic arthritis | See: Systemic-onset juvenile rheumatoid arthritis (still's disease). (12 Dec 1998) |
| juvenile chronic arthritis | juvenile arthritis |
| juvenile chronic arthritis, systemic-onset | See: Juvenile rheumatoid arthritis, systemic-onset (still's disease). (12 Dec 1998) |
| acute inflammatory polyneuropathy | <neurology, syndrome> Acute infective polyneuritis that results in a form of peripheral neuropathy with temporary loss of movement and sensation due to inflammation of multiple nerves and loss of myelin. The exact cause is unknown but has been associated with an abnormal immune response to viral infection, particularly cytomegalovirus infection, in which there is cell-mediated immunity to a component of myelin. The disease may be autoimmune in origin and complete recovery can take up to six months. Synonym: Guillain-Barre syndrome (12 Jul 2000) |
| anti-inflammatory | Counteracting or suppressing inflammation. (18 Nov 1997) |
| anti-inflammatory agent | Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process. (12 Dec 1998) |
| anti-inflammatory agent, non-steroidal | Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5) (12 Dec 1998) |
| anti-inflammatory agent, steroidal | Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents. (12 Dec 1998) |
| anti-inflammatory agent, topical | Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application. (12 Dec 1998) |
| macrophage inflammatory protein | <cytokine> A chemokine that is chemotactic for neutrophils and monocytes, stimulates macrophages, and may play a role in regulating haematopoiesis. Its two variants, mip-1alpha and mip-1beta, are 60% homologous to each other. They are heparin-binding proteins that exhibit a number of inflammatory and immunoregulatory activities. Originally identified as secretory products of macrophages, these chemokines are produced by a variety of cell types including neutrophils, fibroblasts, and epithelial cells. They most likely also play a significant role in respiratory tract defenses. (20 Sep 2002) |
| pelvic inflammatory disease | <disease> An inflammatory process that results from other pelvic diseases, may result from gonorrhoea, chlamydia, ovarian cystic disease or postpartum infections. (27 Sep 1997) |
| non-steroidal anti-inflammatory | <pharmacology> A large group of anti-inflammatory agents that work by inhibiting the production of prostaglandins. They exert anti-inflammatory, analgesic and antipyretic actions. Examples include: ibuprofen, ketoprofen, piroxicam, naproxen, sulindac, aspirin, choline subsalicylate, diflunisal, fenoprofen, indomethacin, meclofenamate, salsalate, tolmetin and magnesium salicylate. A contrast is made with steroidal compounds (such as hydrocortisone or prednisone) exerting anti-inflammatory activity. Acronym: NSAID (05 May 2002) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|